-
公开(公告)号：US11679145B2
公开(公告)日：2023-06-20
申请号：US17117643
申请日：2020-12-10
Applicant: FERRING B.V.
Inventor： Joan-Carles Arce , Jane Ruman , Patrick Heiser
CPC classification number: A61K38/24 , A61B17/425 , A61K45/06 , C12N5/0604 , C12N5/0609 , G01N33/74
Abstract: The present invention relates to improved assisted reproductive technology using highly purified menotropin (HP-hMG) to stimulate follicle development in controlled ovarian stimulation, particularly in women at risk of a high ovarian response to controlled ovarian stimulation.
-
公开(公告)号：US10413592B2
公开(公告)日：2019-09-17
申请号：US15053116
申请日：2016-02-25
Applicant: FERRING B.V.
Inventor： Joan-Carles Arce , Jane Ruman
Abstract: The present invention relates to improved assisted reproductive technology using highly purified menotropin (HP-hMG) to stimulate follicle development in controlled ovarian stimulation, particularly in women at risk of a high ovarian response to controlled ovarian stimulation.
-
公开(公告)号：US11291708B2
公开(公告)日：2022-04-05
申请号：US16851260
申请日：2020-04-17
Applicant: FERRING B.V.
Inventor： Joan-Carles Arce
IPC: A61K38/24
Abstract: Preparations including FSH, for example recombinant FSH, for use in the treatment of infertility.
-
公开(公告)号：US10183029B2
公开(公告)日：2019-01-22
申请号：US15408256
申请日：2017-01-17
Applicant: Ferring B.V.
Inventor： Joan-Carles Arce
IPC: A61B17/435 , A61K31/57 , A61K31/404 , A61K38/11 , A61K38/12 , A61K9/00 , A61K45/06 , A61K31/4045 , A61K31/565
Abstract: The present invention relates to the use of an oxytocin receptor antagonist in females undergoing embryo transfer as part of an assisted reproductive technology. In particular, methods are provided for increasing ongoing implantation rate, increasing ongoing pregnancy rate, increasing clinical pregnancy rate, and/or increasing live birth rate in a female subject undergoing embryo transfer. Specifically, the antagonists are released in the luteal phase when the endometrium is receptive for embryo implantation and/or when the embryo has reached the blastocyst-stage.
-
公开(公告)号：US20220370567A1
公开(公告)日：2022-11-24
申请号：US17709305
申请日：2022-03-30
Applicant: FERRING B.V.
Inventor： Joan-Carles Arce
IPC: A61K38/24
Abstract: Preparations including FSH, for example recombinant FSH, for use in the treatment of infertility.
-
Patent Agency Ranking
公开(公告)号：US10688106B2
公开(公告)日：2020-06-23
申请号：US15538639
申请日：2015-12-21
Applicant: Ferring B.V.
Inventor： Joan-Carles Arce
IPC: A61K31/57 , A61K31/404 , A61B17/435 , A61K38/095 , A61K38/12 , A61K45/06 , A61K31/4045 , A61K31/565 , A61K9/00
Abstract: The present invention relates to the use of an oxytocin receptor antagonist in females undergoing embryo transfer as part of an assisted reproductive technology. In particular, methods are provided for increasing ongoing implantation rate, increasing ongoing pregnancy rate, increasing clinical pregnancy rate, and/or increasing live birth rate in a female subject undergoing embryo transfer. Specifically, the antagonists are released in the luteal phase when the endometrium is receptive for embryo implantation and/or when the embryo has reached the blastocyst-stage.
-
公开(公告)号：US20180028620A1
公开(公告)日：2018-02-01
申请号：US15637962
申请日：2017-06-29
Applicant: Ferring B.V.
Inventor： Joan-Carles Arce
IPC: A61K38/24
Abstract: Preparations including FSH, for example recombinant FSH, for use in the treatment of infertility.
-
公开(公告)号：US11752157B2
公开(公告)日：2023-09-12
申请号：US16877186
申请日：2020-05-18
Applicant: Ferring B.V.
Inventor： Joan-Carles Arce
IPC: A61K31/404 , A61B17/435 , A61K31/57 , A61K38/095 , A61K38/12 , A61K45/06 , A61K31/4045 , A61K31/565 , A61K9/00
CPC classification number: A61K31/57 , A61B17/435 , A61K9/0019 , A61K9/0034 , A61K31/404 , A61K31/4045 , A61K31/565 , A61K38/095 , A61K38/12 , A61K45/06 , A61K31/4045 , A61K2300/00 , A61K31/57 , A61K2300/00 , A61K31/565 , A61K2300/00
Abstract: The present invention relates to the use of an oxytocin receptor antagonist in females undergoing embryo transfer as part of an assisted reproductive technology. In particular, methods are provided for increasing ongoing implantation rate, increasing ongoing pregnancy rate, increasing clinical pregnancy rate, and/or increasing live birth rate in a female subject undergoing embryo transfer. Specifically, the antagonists are released in the luteal phase when the endometrium is receptive for embryo implantation and/or when the embryo has reached the blastocyst-stage.
-
公开(公告)号：US20200345814A1
公开(公告)日：2020-11-05
申请号：US16851260
申请日：2020-04-17
Applicant: FERRING B.V.
Inventor： Joan-Carles Arce
IPC: A61K38/24
Abstract: Preparations including FSH, for example recombinant FSH, for use in the treatment of infertility.
-
公开(公告)号：US20160250296A1
公开(公告)日：2016-09-01
申请号：US15053116
申请日：2016-02-25
Applicant: FERRING B.V.
Inventor： Joan-Carles Arce , Jane Ruman
CPC classification number: A61K38/24 , A61B17/425 , A61K45/06 , C12N5/0604 , C12N5/0609 , G01N33/74
Abstract: The present invention relates to improved assisted reproductive technology using highly purified menotropin (HP-hMG) to stimulate follicle development in controlled ovarian stimulation, particularly in women at risk of a high ovarian response to controlled ovarian stimulation.
Abstract translation: 本发明涉及使用高度纯化的促黄体素（HP-hMG）在受控的卵巢刺激中刺激卵泡发育的改善的辅助生殖技术，特别是在受控卵巢刺激的卵巢反应高的妇女中。
-
-
-
-
-
-
-
-
-
Search Results
17
records
(took 0.014 seconds)
